Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Lai

Showing results (151-160 of 209) with videos related to

Pageof 21
Sort By:
Neurosurgery|May 5, 2020
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor BurdenKunal S Patel, Richard G Everson, Jingwen Yao, et al.
Blood|November 18, 2022
Determining venous thromboembolism risk in patients with adult-type diffuse gliomaKirsten Bell Burdett, Dusten Unruh, Michael Drumm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology Advances|June 25, 2021
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Neuro-Oncology Advances|March 29, 2021
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2014
Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomasSichen Li, Reshmi Chowdhury, Fei Liu, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Cell|May 29, 2018
Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 AcetylomeBrian T Weinert, Takeo Narita, Shankha Satpathy, et al.
Journal of Neuro-Oncology|March 7, 2019
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationFei Liu, Christopher D Cox, Reshmi Chowdhury, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:
Pageof 21
Neurosurgery|May 5, 2020
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor BurdenKunal S Patel, Richard G Everson, Jingwen Yao, et al.
Blood|November 18, 2022
Determining venous thromboembolism risk in patients with adult-type diffuse gliomaKirsten Bell Burdett, Dusten Unruh, Michael Drumm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio TrialThomas Sandmann, Richard Bourgon, Josep Garcia, et al.
Neuro-Oncology Advances|June 25, 2021
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Neuro-Oncology Advances|March 29, 2021
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomasRadwa Sharaf, Dean C Pavlick, Garrett M Frampton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2014
Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomasSichen Li, Reshmi Chowdhury, Fei Liu, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Cell|May 29, 2018
Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 AcetylomeBrian T Weinert, Takeo Narita, Shankha Satpathy, et al.
Journal of Neuro-Oncology|March 7, 2019
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationFei Liu, Christopher D Cox, Reshmi Chowdhury, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Pageof 21